New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
16:32 EDTNRXNephrogenex initiates pivotal oral Pyridorin Phase 3 study
NephroGenex announced it has initiated patient enrollment in the first of two pivotal Phase 3 studies in the PIONEER program for oral Pyridorin. The trial will evaluate the safety and efficacy of Pyridorin in slowing disease progression in patients with diabetic nephropathy.
News For NRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
08:03 EDTNRXNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the companyís Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
July 17, 2015
09:07 EDTNRXOn The Fly: Pre-market Movers
Subscribe for More Information
July 16, 2015
17:43 EDTNRXNephroGenex 1.5M share Secondary priced at $5.00
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use